FONDAZIONE GIANNI BONADONNA AND THERAPEUTIC INNOVATION
Oncology is a front runner of modern medicine, in which science, research and innovation in treatment, surgery, radiotherapy and diagnostics are merging elements to achieve the best results in favour of cancer patients.
The growing commitment of the major Pharmaceutical Companies, new Biotechnology realities and the increasing knowledge of therapeutic targets contribute to new availabilities of approaches in treatments.
In the constantly evolving scenario of Oncology medicine an appropriate coordination of efforts and skills to manage the transition from the laboratory to the clinic is often lacking: the aim of Fondazione Gianni Bonadonna is favour the rapid application of new therapies, as well as the understanding of their mechanisms of effectiveness or resistance.
The coordination of the research of Fondazione Gianni Bonadonna’s is entrusted to Diego Tosi, medical oncologist at Institut du Cancer de Montpellier (ICM, France) and researcher at Istitut de Recherche en Cancérologie de Montpellier (IRCM), and currently Head of Early Clinical Trial Unit at ICM, where he is conducting several projects on clinical and preclinical research.
The trials sponsored by Fondazione Gianni Bonadonna are coordinated by Michelangelo Tech Srl, Contract Research Organisation (CRO) owned by Fondazione Michelangelo and founded in 2001 with the aim to contribute to the innovation in research in oncology and improve therapeutic options for cancer patients.
The Michelangelo Tech’s operates to conduct accrding to the highest standard of GCP the research goals of Fondazione Michelangelo and Fondazione Gianni Bonadonna.